AU2002338667B2 - Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture - Google Patents

Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture Download PDF

Info

Publication number
AU2002338667B2
AU2002338667B2 AU2002338667A AU2002338667A AU2002338667B2 AU 2002338667 B2 AU2002338667 B2 AU 2002338667B2 AU 2002338667 A AU2002338667 A AU 2002338667A AU 2002338667 A AU2002338667 A AU 2002338667A AU 2002338667 B2 AU2002338667 B2 AU 2002338667B2
Authority
AU
Australia
Prior art keywords
virus
culture
medium
viruses
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002338667A
Other languages
English (en)
Other versions
AU2002338667A1 (en
Inventor
Christian Frech
Jens-Peter Gregersen
Holger Lubben
Jurgen Vorlop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002338667A1 publication Critical patent/AU2002338667A1/en
Priority to AU2008207588A priority Critical patent/AU2008207588B2/en
Application granted granted Critical
Publication of AU2002338667B2 publication Critical patent/AU2002338667B2/en
Assigned to Noartis Vaccines and Diagnostics GmbH & Co. KG reassignment Noartis Vaccines and Diagnostics GmbH & Co. KG Alteration of Name(s) in Register under S187 Assignors: CHIRON BEHRING GMBH & CO.
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS GMBH reassignment NOVARTIS VACCINES AND DIAGNOSTICS GMBH Request to Amend Deed and Register Assignors: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16751—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002338667A 2001-09-12 2002-09-11 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture Expired AU2002338667B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008207588A AU2008207588B2 (en) 2001-09-12 2008-08-28 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10144906A DE10144906B4 (de) 2001-09-12 2001-09-12 Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144906.2 2001-09-12
PCT/EP2002/010208 WO2003023021A2 (de) 2001-09-12 2002-09-11 Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008207588A Division AU2008207588B2 (en) 2001-09-12 2008-08-28 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture

Publications (2)

Publication Number Publication Date
AU2002338667A1 AU2002338667A1 (en) 2003-06-19
AU2002338667B2 true AU2002338667B2 (en) 2008-10-02

Family

ID=7698764

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002338667A Expired AU2002338667B2 (en) 2001-09-12 2002-09-11 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
AU2008207588A Expired AU2008207588B2 (en) 2001-09-12 2008-08-28 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008207588A Expired AU2008207588B2 (en) 2001-09-12 2008-08-28 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture

Country Status (16)

Country Link
US (1) US10329536B2 (enExample)
EP (3) EP1427815B1 (enExample)
JP (4) JP2005532779A (enExample)
KR (1) KR100999345B1 (enExample)
AT (2) ATE512213T1 (enExample)
AU (2) AU2002338667B2 (enExample)
BR (1) BR0212470A (enExample)
CA (1) CA2455189C (enExample)
CY (2) CY1110964T1 (enExample)
DE (3) DE10144906B4 (enExample)
DK (2) DK1427815T3 (enExample)
ES (2) ES2351300T3 (enExample)
NZ (1) NZ532202A (enExample)
PT (2) PT2011862E (enExample)
SI (1) SI1427815T1 (enExample)
WO (1) WO2003023021A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237246A (zh) * 2019-07-25 2019-09-17 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感(h9)灭活疫苗的方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551640A (en) * 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
EP2578229B1 (en) 2004-09-09 2013-07-10 Novartis Vaccines and Diagnostics GmbH Decreasing potential iatrogenic risks associated with vaccine antigens
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2069480B1 (en) 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
US9439960B2 (en) * 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP5548207B2 (ja) 2008-09-24 2014-07-16 メディミューン，エルエルシー ウイルスの精製方法
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
WO2011011660A2 (en) 2009-07-23 2011-01-27 Xcellerex, Inc. Drain down and re-feed of microcarrier bioreactor
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US20110142863A1 (en) * 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2562818T3 (es) * 2010-05-03 2016-03-08 Glaxosmithkline Biologicals S.A. Procedimiento de inactivación del virus de la gripe
EP2566323A2 (en) 2010-05-06 2013-03-13 Novartis AG Organic peroxide compounds for microorganism inactivation
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
AU2011262309B2 (en) 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
WO2012033236A1 (ko) 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
WO2012082723A2 (en) 2010-12-15 2012-06-21 Emd Millipore Corporation Purification of immunogens using a non-polysaccharide matrix
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
WO2017072744A1 (en) 2015-10-30 2017-05-04 National Institute Of Infectious Diseases And Vaccinology, National Health Research Institutes Mdck suspension cell lines in serum-free, chemically-defined media for vaccine production
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CA3183701A1 (en) * 2020-06-22 2021-12-30 Sung Jin Kim Method for large scale-production of vaccinia virus using suspension cells
WO2022125793A1 (en) * 2020-12-10 2022-06-16 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037001A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
USRE33164E (en) 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US4500513A (en) 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US5013663A (en) 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
EP0389925B1 (en) 1989-03-29 1995-12-27 The Research Foundation Of State University Of New York A method for purifying an outer membrane protein of Haemophilus influenzae
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
MY107664A (en) * 1991-01-17 1996-05-30 Kao Corp Novel alkaline proteinase and process for producing the same
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
EP0592692B1 (en) * 1992-05-01 1997-07-02 Teijin Limited Fed batch process for protein secreting cells
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
ES2323490T3 (es) * 1994-11-10 2009-07-17 Baxter Healthcare Sa Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas.
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
AU694592B2 (en) 1994-11-16 1998-07-23 St. Jude Children's Research Hospital Novel replication process
US5646033A (en) 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
JPH11513372A (ja) 1995-09-22 1999-11-16 コノート ラボラトリーズ リミテッド パラインフルエンザウイルスの糖タンパクおよびワクチン
CN1618464A (zh) * 1998-10-05 2005-05-25 财团法人阪大微生物病研究会 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
WO2001029246A1 (fr) * 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
DE60142506D1 (de) 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
US20060147477A1 (en) 2002-06-11 2006-07-06 Glaxo Group Limited Immunogenic compositions
MXPA05009580A (es) 2003-03-07 2005-10-19 Merck & Co Inc Vacuna contra el virus de la influenza.
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
EP1863529A1 (en) 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
AU2011225748A1 (en) 2010-03-08 2012-09-13 Novartis Ag Methods of testing for intracellular pathogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037001A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Merten et al, Adv in Expt Med and Biol (1996), vol 397: 141-151 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237246A (zh) * 2019-07-25 2019-09-17 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感(h9)灭活疫苗的方法
CN110237246B (zh) * 2019-07-25 2022-11-15 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感（h9）灭活疫苗的方法

Also Published As

Publication number Publication date
EP1427815B1 (de) 2010-09-01
JP5264812B2 (ja) 2013-08-14
ATE512213T1 (de) 2011-06-15
EP2011862A1 (de) 2009-01-07
KR20050027165A (ko) 2005-03-17
EP2011862B1 (de) 2011-06-08
SI1427815T1 (sl) 2010-12-31
JP2005532779A (ja) 2005-11-04
US20050118140A1 (en) 2005-06-02
ATE479742T1 (de) 2010-09-15
PT1427815E (pt) 2010-12-07
CY1110964T1 (el) 2015-06-11
CA2455189A1 (en) 2003-03-20
JP2010138205A (ja) 2010-06-24
ES2367833T3 (es) 2011-11-08
DK1427815T3 (da) 2010-12-06
PT2011862E (pt) 2011-09-16
JP2008289499A (ja) 2008-12-04
AU2008207588A1 (en) 2008-09-18
DE122011000005I1 (de) 2011-06-16
CA2455189C (en) 2012-01-10
EP1427815A2 (de) 2004-06-16
DE50214630D1 (de) 2010-10-14
DE10144906B4 (de) 2013-11-28
WO2003023021A2 (de) 2003-03-20
BR0212470A (pt) 2004-08-24
KR100999345B1 (ko) 2010-12-09
DK2011862T3 (da) 2011-09-12
HK1062030A1 (zh) 2004-10-15
ES2351300T3 (es) 2011-02-02
US10329536B2 (en) 2019-06-25
CY1113241T1 (el) 2016-04-13
NZ532202A (en) 2006-08-31
WO2003023021A3 (de) 2003-11-06
EP2216400A1 (de) 2010-08-11
AU2008207588B2 (en) 2012-01-19
DE10144906A1 (de) 2003-03-27
JP2011212021A (ja) 2011-10-27

Similar Documents

Publication Publication Date Title
AU2002338667B2 (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
AU2002338666B2 (en) Multiplication of viruses in a cell culture
JP5264843B2 (ja) 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス
CA2205015C (en) Method for producing biologicals in protein-free culture
RU2491339C2 (ru) Способ репликации вируса гриппа в культуре
JP2012005502A (ja) インフルエンザウイルスの複製のための動物細胞および方法
Arifin et al. Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2‐litre stirred tank bioreactor
BRPI0914805B1 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
Arifin et al. Research Article Production of Newcastle Disease Virus by Vero Cells Grown on Cytodex 1 Microcarriers in a 2-Litre Stirred Tank Bioreactor
HK1062029B (en) Multiplication of viruses in a cell culture
HK1149046A (en) Method for manufacturing an active component of a medicine or diagnosis agent in mdcj cell suspension culture
HK1062030B (en) Methods for the industrial production of vaccines

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 11 SEP 2007 TO 11 NOV 2008 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 11 NOV 2008.

FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 23, NO 15, PAGE(S) 7650 UNDER THE HEADING CHANGE OF NAMES(S) OF APPLICANT(S), SECTION 104 - 2002 UNDER THE NAME NOARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG, APPLICATION NO. 2002338667, UNDER INID (71), CORRECT THE NAME TO READ NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG

PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER WAS: NOVARTIS VACCINES AND DIAGNOSTICS GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired